Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method

Journal of Clinical Psychiatry

Volumn 64, Issue 6, 2003, Pages 680-690

  Post, Robert M ^a   Denicoff, Kirk D ^a   Leverich, Gabriele S ^a   Altshuler, Lori L ^b   Frye, Mark A ^b   Suppes, Trisha M ^c   Rush, A John ^c   Keck Jr , Paul E ^d   McElroy, Susan L ^d   Luckenbaugh, David A ^a   Pollio, Chad ^a   Kupka, Ralph ^e   Nolen, Willem A ^e  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLORAZEPATE DIPOTASSIUM; CLOZAPINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE SODIUM; LITHIUM; LORAZEPAM; MOCLOBEMIDE; MOLINDONE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PAROXETINE; PERPHENAZINE; PHENELZINE; PIMOZIDE; PROCHLORPERAZINE MALEATE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; TEMAZEPAM; THIORIDAZINE; TIOTIXENE; TOPIRAMATE; TRANYLCYPROMINE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADULT; ANAMNESIS; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DEPRESSION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; JOB PERFORMANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR AFFECTIVE DISORDER; MAJOR CLINICAL STUDY; MALE; MANIA; MINIMAL RESIDUAL DISEASE; MOOD DISORDER; MORBIDITY; OUTCOMES RESEARCH; OUTPATIENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RATING SCALE; SUBSTANCE ABUSE; SYMPTOM; TECHNIQUE;

EID: 0038604854     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0610     Document Type: Article

References (45)

1. Benazzi F. Prevalence and clinical correlates of residual depressive symptoms in bipolar II disorder. Psychother Psychosom 2001;70:232-238
2. O'Connell RA, Mayo JA, Flatow L, et al. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991;159:123-129
3. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-1493
4. Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull 1996;32:47-54
5. Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-35
6. Gitlin MJ, Swendsen J, Heller TL, et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-1640
7. Vestergaard P. Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 1992;7:249-259
8. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
9. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 1987;44:540-548
10. Coryell W, Turvey C, Endicott J, et al. Bipolar I affective disorder: predictors of outcome after 15 years. J Affect Disord 1998;50:109-116
11. Kraepelin E. Manic-Depressive Insanity and Paranoia. Edinburgh, Scotland: ES Livingstone; 1921
12. Leverich GS, Post RM. Life charting the course of bipolar disorder. Curr Rev Mood Anxiety Disord 1996;1:48-61
13. Leverich GS, Post RM. Life charting of affective disorders. CNS Spectrums 1998;3:21-37
14. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). J Psychiatr Res 1997;31:593-603
15. Denicoff KD, Leverich GS, Nolen WA, et al. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med 2000;30:1391-1397
16. Leverich GS, Nolen WA, Rush AJ, et al. The Stanley Foundation Bipolar Treatment Outcome Network, 1: longitudinal methodology. J Affect Disord 2001;67:33-44
17. Post RM, Nolen WA, Kupka RW, et al. The Stanley Foundation Bipolar Network, I: rationale and methods. Br J Psychiatry 2001;178:S169-S176
18. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 1996
19. Suppes T, Leverich GS, Keck PE, et al. The Stanley Foundation Bipolar Treatment Outcome Network, 2: demographics and illness characteristics of the first 261 patients. J Affect Disord 2001;67:45-59
20. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001;158:420-426
21. Kupka RW, Nolen WA, Altshuler LL, et al. The Stanley Foundation Bipolar Network, 2: preliminary summary of demographics, course of illness and response to novel treatments. Br J Psychiatry 2001;178: S177-S183
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
23. Denicoff KD, Blake KD, Smith-Jackson EE, et al. Morbidity in treated bipolar disorder: a one year prospective study using daily life chart ratings. Depression 1994;2:95-104
24. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229-233
25. Kramlinger KG, Post RM. Ultra-rapid and ultradian cycling in bipolar affective illness. Br J Psychiatry 1996;168:314-323
26. Post RM, Altshuler LL, Frye MA, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001;3:259-265
27. Allilaire JF, Hantouche EG, Sechter D, et al. Frequence et aspects cliniques du trouble bipolaire II dans une etude multicentrique francaise: EPIDEP. [Frequency and clinical aspects of bipolar II disorder in a French multicenter study: EPIDEP.] Encephale 2001;27:149-158
28. Coryell W, Endicott J, Maser JD, et al. The likelihood of recurrence in bipolar affective disorder: the importance of episode recency. J Affect Disord 1995;33:201-206
29. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15
30. Tohen M, Hennen J, Zarate CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000;157:220-228
31. Keck PE Jr, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998;155:646-652
32. Tohen M, Strakowski SM, Zarate C Jr, et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry 2000;48:467-476
33. Robb JC, Cooke RG, Devins GM, et al. Quality of life and lifestyle disruption in euthymic bipolar disorder. J Psychiatr Res 1997;31:509-517
34. Judd LL, Akiskal HS. Delineating the longitudinal structure of depressive illness: beyond clinical subtypes and duration thresholds. Pharmacopsychiatry 2000;33:3-7
35. Kendell RE. The classification of depressions: a review of contemporary confusion. Br J Psychiatry 1976;129:15-28
36. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855
37. Post RM, Weiss SRB, Leverich GS, et al. Sensitization and kindling-like phenomena in bipolar disorder: implications for psychopharmacology. Clin Neurosci Res 2001;1:69-81
38. Keller MB, Lavori PW, Kane JM, et al. Subsyndromal symptoms in bipolar disorder: a comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 1992;49:371-376
39. Goldberg JF, Harrow M, Sands JR. Lithium and the longitudinal course of bipolar illness. Psychiatr Ann 1996;26:651-658
40. Suppes T, Brown ES, McElroy SL, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999;53:95-98
41. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025-1033
42. Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull 1990;26:409-427
43. Prien RF, Rush AJ. National Institute of Mental Health Workshop report on the treatment of bipolar disorder. Biol Psychiatry 1996;40:215-220
44. Goodwin G. Perspectives for clinical research on bipolar disorders in the new millennium. Bipolar Disord 2000;2:302-304
45. Baldessarini RJ, Tondo L. Does lithium treatment still work? evidence of stable responses over three decades. Arch Gen Psychiatry 2000;57:187-190